(Zero Hedge)—A Chinese patent for a COVID-19 vaccine filed just weeks after the virus emerged in the United States is drawing fresh scrutiny from U.S. investigators examining the origins of the pandemic and potential efforts to conceal early information about the virus.
The February 24, 2020, patent application – submitted by three Chinese entities affiliated with the People’s Liberation Army – outlines a process for developing a “COVID-19 protein vaccine.” The document, which predates the World Health Organization’s declaration of a global pandemic, lists 11 inventors. Among them are two scientists affiliated with a neuroscience institute within the Chinese military – a detail that has puzzled U.S. officials, given that neurological symptoms of COVID-19 were not widely known or studied at the time.
The participation of researchers from the Institute of Military Cognition and Brain Sciences – a division of the Academy of Military Sciences in Beijing – has raised particular concern among federal investigators. The institute, which has drawn attention from U.S. defense analysts in recent years, plays a role in the Chinese military’s emerging focus on cognitive warfare – the strategic use of neuroscience in national defense, Just the News reports.
“Significantly, their published research provided limited, or no data of neuropathology observed in the experimental animals, or the neuroprotection afforded by the vaccine,” wrote Dr. Robert Kadlec, a former senior Health and Human Services official, in a 2023 report examining the origins of the pandemic. “Institute of Military Cognition researchers’ involvement in such studies suggest an interest in the vaccine’s protection against SARS-CoV-2 early in the outbreak before evidence of its neurological effects were widely known.”
Dr. Kadlec, who served in the Trump administration and played a central role in Operation Warp Speed, was among the first U.S. officials to question why neuroscientists were included in early Chinese vaccine development. His report, titled A Critical Review of COVID-19 Origins: Hidden in Plain Sight, was published last September.
Other figures on Capitol Hill have voiced similar concerns. Representative Darin LaHood, Republican of Illinois and a member of the House Intelligence Committee, recently stated that the cover-up of COVID-19’s early emergence in China should be understood in the context of Beijing’s broader strategic ambitions.
“China has a plan to replace the United States, and they’re working at it every single day,” Mr. LaHood said in a podcast interview this week. “They want to beat us technologically, militarily, economically and diplomatically. And the sooner we wake up to that, the better.”
“… And we’ve seen evidence of this through Huawei and what China… has done with Huawei, what they’ve done with TikTok, what they’ve done now with Deep Seek, what they did… in terms of lying and being deceitful with the Wuhan virus,” he continued.
Possibly part of that effort: Chinese military strategists are actively developing new methods for using neurology to gain advantages on the battlefield, according to Elsa Kania, Adjunct Senior Fellow at the Center for New American Security.
“On the battlefield, attempts to undermine an adversary could include interfering with the adversary’s capacity for cognition, whether through manipulation or out-right destruction, from disrupting the flow of data to exploiting ideology or emotion,” she wrote in January 2020 for U.S. National Defense University magazine, Prism, which focuses on “emerging disruptive technologies.” -Just the News
At the center of the February 2020 vaccine patent is Zhou Yusen, a senior military scientist at the State Key Laboratory of Pathogen and Biosecurity. Zhou, who previously collaborated with the Wuhan Institute of Virology on SARS and MERS vaccines, is among the 11 listed inventors. According to Senate researchers, Zhou died under unclear circumstances in the months following the outbreak.
The presence of neuroscientists on the patent application – including Yan Li and Gencheng Han – has intensified questions about what Chinese scientists may have known about COVID-19’s broader physiological effects in the earliest days of the outbreak. A separate scientific paper identifies both researchers as members of the Institute of Military Cognition and Brain Sciences. At the time the patent was filed, neurological symptoms of COVID-19 were not widely reported or understood by Western scientists.
Subsequent studies have shown that COVID-19 can have long-lasting neurological effects. A 2022 study published in Nature found that survivors of COVID-19 faced elevated risks of conditions including strokes, memory disorders, migraines, and seizures in the months following infection. Researchers at Duke University reported neurocognitive impairments and sleep disturbances lasting up to three months in some patients.
The earliest Chinese study documenting COVID-19’s neurological symptoms was published in April 2020. According to the study, which was based on clinical data from Wuhan, patient monitoring was still underway five days before the vaccine patent was filed.
The new questions about the early vaccine patent follow revelations this week that a Defense Intelligence Agency unit concluded in mid-2020 that COVID-19 was likely genetically engineered and leaked from a laboratory. That internal study, which described the virus’s spike protein as a “chimera,” was not included in official U.S. intelligence assessments. It was only released following Freedom of Information Act requests and is now part of the ongoing congressional investigation.
The Defense Intelligence Agency analysis traced elements of the COVID-19 virus back to a decade-old scientific manuscript published by the Wuhan Institute of Virology, which has worked closely with the Chinese military on coronavirus research, according to the U.S. intelligence community.
Taken together, these findings are intensifying scrutiny of early Chinese responses to the virus, as well as raising new questions about what information may have been known – and withheld – in the earliest stages of the global pandemic.
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.